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Key Clinical Message
Atypical manifestation of Huntington’s disease (HD) could inform ongoing
research into HD genetic modifiers not present in the primarily European pop-
ulations studied to date. This work demonstrates that expanding HD genetic
testing into under-resourced healthcare settings can benefit both local commu-
nities and ongoing research into HD etiology and new therapies.
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Prior to enrollment, written informed consent was
obtained from all study participants. The study was
approved by the Ethical Review Committee (ERC) of
Bangladesh Medical Research Council (BMRC).
Here, we describe an extended family in northern Ban-
gladesh with eight members affected with Huntington’s
disease (HD) exhibiting atypical clinical features. All eight
have the CAG repeat expansion in exon 1 of HTT gene
and do not carry mutations associated with other HD-like
disorders, Wilson’s disease, or other neurodegenerative
diseases. The affected family, in northern Bangladesh, has
eight living members with Huntington’s disease (HD), all
with atypical clinical features. The disorder appeared
almost 130 years ago in one of the two siblings. All
affected individuals are progeny of the affected sibling,
and no progeny of the healthy sibling are affected. No
consanguineous marriages are reported for the study par-
ticipants. The age of onset decreased from 65 to 20 years
over five generations, and this information is consistent
with Huntington’s disease. Clinical information was
obtained for all eight patients. All of the patients (100%)
exhibited mild jerky movement of fingers and slow move-
ment of eyes as the first detectable clinical symptoms.
Four of the patients (50%) exhibited moderate-to-severe
chorea, whereas the remaining four cases (50%) did not
exhibit any choreatic movement disorder except mild
jerky movement of fingers and slow movement of eyes.
All eight patients (100%) seemed normal in terms of cog-
nitive function because there was no significant dementia
as manifested by mini-mental state examination. In
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addition, none of the patients did show any psychiatric
disturbances. Although three cases (37.5%) showed char-
acteristic features of anxiety, there was no tendency of
committing suicide. It is mentionable here that one
patient had severe chorea characterized by balanced trou-
ble, clumsiness, tremor, significant weight loss, fidgeting,
facial grimaces, increased appetite, less control over hand-
writing, rigidity, speech difficulties, grunting and abnor-
mal speech patterns, inability to control speed and force
of movement, general weakness, and impairment of
superficial sensation. However, the clinical symptoms, as
manifested by brain imaging and mini-mental state exam-
ination, were not fully consistent with typical Hunting-
ton’s disease (HD) or any other choreatic movement-
associated neurodegenerative diseases including HD-like
disorders or Wilson’s disease. Analysis of blood parame-
ters like total bilirubin, ALT (alanine aminotransferase),
and ceruloplasmin as well as Kayser–Fleischer (K-F) ring
test did not show any abnormal results (data not shown),
excluding the possibility Wilson’s disease. MRI examina-
tion of the patient’s brain did not reveal pathology typical
of Huntington’s disease (Fig. 1) [1, 2]. Putamen and Cau-
date are the primary sites to be affected for the structural
changes in Huntington’s disease. No changes were evident
in the caudate nucleus and striatum regions like putamen
and globus pallidus, although mild cerebellar atrophy was
observed (Fig. 1).
Because of the atypical clinical symptoms, genetic test-
ing using DNA specimens was used to diagnose the disor-
der. We first used PCR-based method to check the length
of the HTT allele [3]. All four unaffected subjects tested
had typical HD allele length of 80–85 bp, while all
affected individuals were heterozygous, with one normal
HD allele and one expanded allele (Fig. 2A). We used
Sanger DNA sequencing to show that the normal allele
had 20 CAG repeats, within the previously reported range
of 6–35 [4, 5]. The expanded allele had either 53 CAG
repeats (seven patients) or 70 CAG repeats (one patient),
confirming the diagnosis of Huntington’s disease (Fig. 2A
and B) [6–9]. The patient with the longer CAG repeat
was just 20 years of age and thus was diagnosed as juve-
nile HD [10–12]. We found no mutations in three genes
(PRNP, JPH3, and TBP) associated with HD-like diseases
HDL 1, HDL 2, and HDL 4, respectively (data not
shown). Major clinical characteristic of typical Hunting-
ton’s disease (HD) is manifested by progressive dementia.
However, HD chorea without dementia [13–15] and
absence of observable atrophy of either cortx or basal
ganglia [16] have been reported. Although CAG repeat
length can be correlated with some of the phenotypic
variability like age of onset and disease severity [17, 18,
19], other genetic modifiers like loci 4p16 (LOD 1.93),
6p21–23 (LOD 2.29), and 6q24–26 (LOD 2.28) may
influence the expression of HD [20].
This extended family pedigree from northern Bangla-
desh exhibited an atypical, undiagnosed neurodegenera-
tive disease. Using genetic sequencing, we diagnosed
Huntington’s disease. Although there are no HD-specific
treatments available yet, the affected people can now
receive symptoms-specific intervention to reduce the
severity of the disease. In addition, genetic counseling can
now help members of this family make informed repro-
ductive decisions. This is the first study on diagnosis of a
neurodegenerative disease using a sequencing-based
(A) (B)
Figure 1. A representative brain MRI examination of patient with severe choreatic movement disorder. Bioimages of brain were obtained using
the 1.5 T MRI systems (GE Healthcare, UK), with transverse T1- and T2-weighted scans at the level of basal ganglia. (A) indicates T1-weighted
scan, whereas (B) indicates T2-weighted scan.
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approach in Bangladesh, paving the way for expansion of
facilities for diagnosis of other genetic disorders. Further-
more, the atypical manifestation of HD in this Banglade-
shi family could inform ongoing research into HD genetic
modifiers not present in the primarily European popula-
tions studied to date. This work demonstrates that
expanding HD genetic testing into under-resourced
healthcare settings can benefit both local communities
and ongoing research into HD disease etiology and new
therapies.
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